Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
502 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Melanoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H1 2015', provides an overview of the Metastatic Melanoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Metastatic Melanoma Overview 12 Therapeutics Development 13 Pipeline Products for Metastatic Melanoma - Overview 13 Pipeline Products for Metastatic Melanoma - Comparative Analysis 14 Metastatic Melanoma - Therapeutics under Development by Companies 15 Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 22 Metastatic Melanoma - Pipeline Products Glance 24 Late Stage Products 24 Clinical Stage Products 25 Early Stage Products 26 Metastatic Melanoma - Products under Development by Companies 27 Metastatic Melanoma - Products under Investigation by Universities/Institutes 35 Metastatic Melanoma - Companies Involved in Therapeutics Development 36 AB Science 36 AbbVie Inc. 37 Adaptimmune Limited 38 Affichem 39 Agalimmune Ltd 40 Agenus, Inc. 41 Altor BioScience Corporation 42 Amgen Inc. 43 Astex Pharmaceuticals, Inc. 44 AstraZeneca PLC 45 AVAX Technologies, Inc. 46 Bayer AG 47 Bioncotech Therapeutics S.L. 48 Bionomics Limited 49 Boehringer Ingelheim GmbH 50 Bristol-Myers Squibb Company 51 Cancer Therapeutics CRC Pty Ltd 52 Cavion LLC 53 Celgene Corporation 54 Celldex Therapeutics, Inc. 55 Colby Pharmaceutical Company 56 CureTech Ltd. 57 Delcath Systems, Inc. 58 Digna Biotech, S.L. 59 DNA Therapeutics S.A. 60 Eisai Co., Ltd. 61 Eli Lilly and Company 62 F. Hoffmann-La Roche Ltd. 63 Galapagos NV 64 Galectin Therapeutics, Inc. 65 GlaxoSmithKline plc 66 HanAll Biopharma Co., Ltd. 67 Immune Design Corp. 68 Immunophotonics Inc 69 ImmuRx, Inc. 70 Incyte Corporation 71 Life Science Pharmaceuticals, Incorporated 72 Lipotek Pty Ltd. 73 Luitpold Pharmaceuticals, Inc. 74 MedImmune, LLC 75 Merck & Co., Inc. 76 Merck KGaA 77 Momenta Pharmaceuticals, Inc. 78 Morphotek, Inc. 79 NeoStem, Inc. 80 NewLink Genetics Corporation 81 Novartis AG 82 Omeros Corporation 83 Oncolytics Biotech Inc. 84 OncoSec Medical Inc. 85 Ono Pharmaceutical Co., Ltd. 86 Onxeo SA 87 Pfizer Inc. 88 Philogen S.p.A. 89 Plexxikon Inc. 90 Polyphor Ltd. 91 Provectus Biopharmaceuticals, Inc. 92 Provenance Biopharmaceuticals Corp. 93 Reata Pharmaceuticals, Inc. 94 Recombio S.L 95 Sanofi 96 SBI Biotech Co., Ltd. 97 Scancell Holdings Plc 98 Takara Bio Inc. 99 Takeda Oncology 100 Ultimovacs AS 101 Vaxeal Holding SA 102 Vical Incorporated 103 WntResearch AB 104 ZIOPHARM Oncology, Inc. 105 Metastatic Melanoma - Therapeutics Assessment 106 Assessment by Monotherapy Products 106 Assessment by Combination Products 107 Assessment by Target 108 Assessment by Mechanism of Action 115 Assessment by Route of Administration 120 Assessment by Molecule Type 122 Drug Profiles 124 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 124 4-Peptide Melanoma Vaccine - Drug Profile 126 A-dmDT390-bisFv - Drug Profile 127 Ad-RTS-IL-12 - Drug Profile 128 AF-122 - Drug Profile 130 ALT-801 - Drug Profile 131 ALT-803 - Drug Profile 133 AMG-232 - Drug Profile 135 Anti-CSPG4-IL2 - Drug Profile 136 austrasulfone - Drug Profile 137 axitinib - Drug Profile 138 BA-015 - Drug Profile 141 bevacizumab - Drug Profile 143 BGJ-398 - Drug Profile 148 binimetinib + encorafenib - Drug Profile 149 BL-011256 - Drug Profile 151 BNC-420 - Drug Profile 152 BO-110 - Drug Profile 153 buparlisib hydrochloride - Drug Profile 154 Cancer Stem Cell Therapy - Drug Profile 158 capmatinib - Drug Profile 159 Cell Therapy to Target HERV-K for Metastatic Melanoma - Drug Profile 161 Cell Therapy to Target Melanoma Antigen Recognized By T-Cells 1 for Metastatic Melanoma - Drug Profile 162 Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 163 Cell Therapy to Target NY-ESO-1 for Metastatic Melanoma - Drug Profile 165 Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 166 cobimetinib - Drug Profile 167 contego - Drug Profile 171 CPC-410 - Drug Profile 173 dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 174 Darleukin - Drug Profile 175 DB-039 - Drug Profile 177 Dendritic Cell Therapy 2 for Metastatic Melanoma - Drug Profile 178 Dendritic Cell Therapy for Metastatic Melanoma - Drug Profile 179 Dendritic Cell Therapy for Metastatic Melanoma and Recurrent Malignant Glioma - Drug Profile 180 Dendritic Cell Therapy to Target gp100, Melan-A, MAGEA3 and Tyrosinase for Metastatic Melanoma - Drug Profile 181 Dendritic Cell Therapy to Target MAGE-A6, MART-1 and Tyrosinase for Metastatic Melanoma - Drug Profile 182 DNA IL-12 - Drug Profile 183 DT-01 - Drug Profile 185 E-6201 - Drug Profile 187 ecromeximab - Drug Profile 189 eltrapuldencel-T - Drug Profile 190 encorafenib - Drug Profile 192 G-305 - Drug Profile 194 glembatumumab vedotin - Drug Profile 195 GLPG-1790 - Drug Profile 197 GR-MD-02 - Drug Profile 198 GSK-2132231A - Drug Profile 200 GSK-2241658A - Drug Profile 201 GSK-2302025A - Drug Profile 202 HF-10 - Drug Profile 203 HL-156CAN - Drug Profile 204 HL-176 - Drug Profile 205 HL-177 - Drug Profile 206 ICOVIR-5 - Drug Profile 207 INCB-24360 - Drug Profile 208 inCVAX - Drug Profile 210 indoximod - Drug Profile 212 ipilimumab - Drug Profile 214 lenvatinib - Drug Profile 218 Lipovaxin-MM - Drug Profile 222 LOC-paclitaxel - Drug Profile 223 LV-305 - Drug Profile 224 LY-3009120 - Drug Profile 225 M-200 - Drug Profile 226 M-Vax - Drug Profile 227 masitinib - Drug Profile 229 melphalan - Drug Profile 232 MelVax - Drug Profile 234 mibefradil dihydrochloride - Drug Profile 235 miRNA-7-5p - Drug Profile 237 MLN-2480 - Drug Profile 238 Monoclonal Antibody to Inhibit CD40 for Metastatic Melanoma - Drug Profile 240 MORAb-050 - Drug Profile 241 MSX-122 - Drug Profile 242 NAcGM3/VSSP Vaccine - Drug Profile 244 necuparanib - Drug Profile 246 nilotinib - Drug Profile 247 nintedanib - Drug Profile 250 nivolumab (recombinant) - Drug Profile 254 onalespib - Drug Profile 259 ontuxizumab - Drug Profile 262 paclitaxel albumin bound - Drug Profile 264 palbociclib - Drug Profile 268 pasireotide - Drug Profile 272 pelareorep - Drug Profile 275 pembrolizumab - Drug Profile 280 pevonedistat hydrochloride - Drug Profile 284 pidilizumab - Drug Profile 286 pimasertib hydrochloride - Drug Profile 288 PLX-3397 - Drug Profile 290 POL-7085 - Drug Profile 292 PV-10 - Drug Profile 293 Q-204 - Drug Profile 296 RAF-265 - Drug Profile 297 Recombinant Protein for Metastatic Melanoma - Drug Profile 298 Recombinant Protein for Oncology - Drug Profile 299 RG-7446 - Drug Profile 300 Riluzole Prodrugs - Drug Profile 302 RTA-408 - Drug Profile 303 SAGEs for Cancer - Drug Profile 306 sagopilone - Drug Profile 307 SAR-260301 - Drug Profile 309 SCIB-1 - Drug Profile 310 selumetinib sulfate - Drug Profile 313 Small Molecule to Antagonize GPR19 for Metastatic Melanoma - Drug Profile 316 Small Molecules to Antagonize ET-B for Oncology - Drug Profile 317 Small Molecules to Inhibit FAK-FLT3-VEGFR3 for Oncology - Drug Profile 318 sunitinib malate - Drug Profile 319 SVX-1 - Drug Profile 323 Synthetic Peptide for Malignant Melanoma - Drug Profile 324 TAK-733 - Drug Profile 325 talimogene laherparepvec - Drug Profile 327 TMECG - Drug Profile 330 TPI-287 - Drug Profile 331 tremelimumab + MEDI-3617 - Drug Profile 333 UV-1 - Drug Profile 334 Vaccine for Cancer - Drug Profile 335 Vaccine for Metastatic Melanoma - Drug Profile 336 Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 337 varlilumab - Drug Profile 338 velimogene aliplasmid - Drug Profile 340 veliparib - Drug Profile 343 vemurafenib - Drug Profile 346 ZSG-101 - Drug Profile 349 ZSG-102 - Drug Profile 350 Metastatic Melanoma - Recent Pipeline Updates 351 Metastatic Melanoma - Dormant Projects 473 Metastatic Melanoma - Discontinued Products 483 Metastatic Melanoma - Product Development Milestones 484 Featured News & Press Releases 484 Appendix 492 Methodology 492 Coverage 492 Secondary Research 492 Primary Research 492 Expert Panel Validation 492 Contact Us 492 Disclaimer 493
List of Tables Number of Products under Development for Metastatic Melanoma, H1 2015 22 Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2015 23 Number of Products under Development by Companies, H1 2015 25 Number of Products under Development by Companies, H1 2015 (Contd..1) 26 Number of Products under Development by Companies, H1 2015 (Contd..2) 27 Number of Products under Development by Companies, H1 2015 (Contd..3) 28 Number of Products under Development by Companies, H1 2015 (Contd..4) 29 Number of Products under Development by Companies, H1 2015 (Contd..5) 30 Number of Products under Investigation by Universities/Institutes, H1 2015 32 Comparative Analysis by Late Stage Development, H1 2015 33 Comparative Analysis by Clinical Stage Development, H1 2015 34 Comparative Analysis by Early Stage Development, H1 2015 35 Products under Development by Companies, H1 2015 36 Products under Development by Companies, H1 2015 (Contd..1) 37 Products under Development by Companies, H1 2015 (Contd..2) 38 Products under Development by Companies, H1 2015 (Contd..3) 39 Products under Development by Companies, H1 2015 (Contd..4) 40 Products under Development by Companies, H1 2015 (Contd..5) 41 Products under Development by Companies, H1 2015 (Contd..6) 42 Products under Development by Companies, H1 2015 (Contd..7) 43 Products under Investigation by Universities/Institutes, H1 2015 44 Metastatic Melanoma - Pipeline by AB Science, H1 2015 45 Metastatic Melanoma - Pipeline by AbbVie Inc., H1 2015 46 Metastatic Melanoma - Pipeline by Adaptimmune Limited, H1 2015 47 Metastatic Melanoma - Pipeline by Affichem, H1 2015 48 Metastatic Melanoma - Pipeline by Agalimmune Ltd, H1 2015 49 Metastatic Melanoma - Pipeline by Agenus, Inc., H1 2015 50 Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H1 2015 51 Metastatic Melanoma - Pipeline by Amgen Inc., H1 2015 52 Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 53 Metastatic Melanoma - Pipeline by AstraZeneca PLC, H1 2015 54 Metastatic Melanoma - Pipeline by AVAX Technologies, Inc., H1 2015 55 Metastatic Melanoma - Pipeline by Bayer AG, H1 2015 56 Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H1 2015 57 Metastatic Melanoma - Pipeline by Bionomics Limited, H1 2015 58 Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 59 Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2015 60 Metastatic Melanoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2015 61 Metastatic Melanoma - Pipeline by Cavion LLC, H1 2015 62 Metastatic Melanoma - Pipeline by Celgene Corporation, H1 2015 63 Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2015 64 Metastatic Melanoma - Pipeline by Colby Pharmaceutical Company, H1 2015 65 Metastatic Melanoma - Pipeline by CureTech Ltd., H1 2015 66 Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H1 2015 67 Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H1 2015 68 Metastatic Melanoma - Pipeline by DNA Therapeutics S.A., H1 2015 69 Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H1 2015 70 Metastatic Melanoma - Pipeline by Eli Lilly and Company, H1 2015 71 Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 72 Metastatic Melanoma - Pipeline by Galapagos NV, H1 2015 73 Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H1 2015 74 Metastatic Melanoma - Pipeline by GlaxoSmithKline plc, H1 2015 75 Metastatic Melanoma - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 76 Metastatic Melanoma - Pipeline by Immune Design Corp., H1 2015 77 Metastatic Melanoma - Pipeline by Immunophotonics Inc, H1 2015 78 Metastatic Melanoma - Pipeline by ImmuRx, Inc., H1 2015 79 Metastatic Melanoma - Pipeline by Incyte Corporation, H1 2015 80 Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2015 81 Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H1 2015 82 Metastatic Melanoma - Pipeline by Luitpold Pharmaceuticals, Inc., H1 2015 83 Metastatic Melanoma - Pipeline by MedImmune, LLC, H1 2015 84 Metastatic Melanoma - Pipeline by Merck & Co., Inc., H1 2015 85 Metastatic Melanoma - Pipeline by Merck KGaA, H1 2015 86 Metastatic Melanoma - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 87 Metastatic Melanoma - Pipeline by Morphotek, Inc., H1 2015 88 Metastatic Melanoma - Pipeline by NeoStem, Inc., H1 2015 89 Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H1 2015 90 Metastatic Melanoma - Pipeline by Novartis AG, H1 2015 91 Metastatic Melanoma - Pipeline by Omeros Corporation, H1 2015 92 Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H1 2015 93 Metastatic Melanoma - Pipeline by OncoSec Medical Inc., H1 2015 94 Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 95 Metastatic Melanoma - Pipeline by Onxeo SA, H1 2015 96 Metastatic Melanoma - Pipeline by Pfizer Inc., H1 2015 97 Metastatic Melanoma - Pipeline by Philogen S.p.A., H1 2015 98 Metastatic Melanoma - Pipeline by Plexxikon Inc., H1 2015 99 Metastatic Melanoma - Pipeline by Polyphor Ltd., H1 2015 100 Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 101 Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H1 2015 102 Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 103 Metastatic Melanoma - Pipeline by Recombio S.L, H1 2015 104 Metastatic Melanoma - Pipeline by Sanofi, H1 2015 105 Metastatic Melanoma - Pipeline by SBI Biotech Co., Ltd., H1 2015 106 Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H1 2015 107 Metastatic Melanoma - Pipeline by Takara Bio Inc., H1 2015 108 Metastatic Melanoma - Pipeline by Takeda Oncology, H1 2015 109 Metastatic Melanoma - Pipeline by Ultimovacs AS, H1 2015 110 Metastatic Melanoma - Pipeline by Vaxeal Holding SA, H1 2015 111 Metastatic Melanoma - Pipeline by Vical Incorporated, H1 2015 112 Metastatic Melanoma - Pipeline by WntResearch AB, H1 2015 113 Metastatic Melanoma - Pipeline by ZIOPHARM Oncology, Inc., H1 2015 114 Assessment by Monotherapy Products, H1 2015 115 Assessment by Combination Products, H1 2015 116 Number of Products by Stage and Target, H1 2015 118 Number of Products by Stage and Mechanism of Action, H1 2015 125 Number of Products by Stage and Route of Administration, H1 2015 130 Number of Products by Stage and Molecule Type, H1 2015 132 Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H1 2015 360 Metastatic Melanoma - Dormant Projects, H1 2015 482 Metastatic Melanoma - Dormant Projects (Contd..1), H1 2015 483 Metastatic Melanoma - Dormant Projects (Contd..2), H1 2015 484 Metastatic Melanoma - Dormant Projects (Contd..3), H1 2015 485 Metastatic Melanoma - Dormant Projects (Contd..4), H1 2015 486 Metastatic Melanoma - Dormant Projects (Contd..5), H1 2015 487 Metastatic Melanoma - Dormant Projects (Contd..6), H1 2015 488 Metastatic Melanoma - Dormant Projects (Contd..7), H1 2015 489 Metastatic Melanoma - Dormant Projects (Contd..8), H1 2015 490 Metastatic Melanoma - Dormant Projects (Contd..9), H1 2015 491 Metastatic Melanoma - Discontinued Products, H1 2015 492
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
